Biogen Inc. (NASDAQ:BIIB) is among the most undervalued NASDAQ stocks to buy now. The company has acquired Alcyone Therapeutics for $85 million, focusing on ThecaFlex DRx for chronic medication delivery without repeated lumbar punctures. Biogen will oversee the development, production, and marketing of ThecaFlex DRx for individuals with spinal muscular atrophy.

Biogen Inc. (NASDAQ:BIIB) is a multinational biopharmaceutical company specializing in innovative treatments for severe complex illnesses. While BIIB shows investment potential, some AI stocks may offer greater upside and lower risk. For a highly undervalued AI stock benefitting from Trump-era tariffs and onshoring trends, check out the best short-term AI stock report.

To further explore top stock picks, consider the 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds. This article is originally published on Insider Monkey.

Read more at Yahoo Finance: Biogen (BIIB) Expands Neurology Pipeline With Alcyone Buyout, Stock Seen Undervalued